trabectedin
Orphan Drug Cold Chain RequiredFDA Approved
Description
Trabectedin is a marine-derived antineoplastic agent approved for treatment of advanced soft tissue sarcomas including liposarcoma and leiomyosarcoma. It binds to the minor groove of DNA, interfering with transcription and DNA repair mechanisms. The drug has shown particular efficacy in myxoid liposarcoma and dedifferentiated liposarcoma subtypes.
Indications & Therapeutic Use
advanced soft tissue sarcoma, liposarcoma, leiomyosarcoma, relapsed ovarian cancer
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
trabectedin
| Generic Name | trabectedin |
| Brands | 1 brand available |
| Active Ingredient | trabectedin |
| Drug Class | advanced soft tissue sarcoma |
| Manufacturer | Janssen/PharmaMar |
| Dosage Forms | IV infusion 0.25mg/mL, 1mg/mL (1mg/4mL, 1mg/20mL vials) |
| Medical Code | L01CX01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00061984 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes